XL 413

Drug Profile

XL 413

Alternative Names: BMS-863233; EXEL 5413; XL-413

Latest Information Update: 04 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CDC7 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 11 Aug 2010 Bristol-Myers Squibb and Exelixis terminate phase I/II trial [NCT00838890] in refractory Haematological malignancies in USA
  • 11 Aug 2010 Bristol-Myers Squibb and Exelixis terminate phase I/II trial [NCT00886782] in late-stage and/or metastatic Solid tumours in USA, Canada and France
  • 27 Nov 2008 Exelixis and Bristol-Myers Squibb select to co-develop XL 413 in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top